A retrospective study of 11 adults using obesity medications and structured exercise found mostly fat loss, highlighting the need for controlled trials.
On September 29, 2026, a report published by Medscape described new findings regarding body composition changes during medication-assisted weight management. The report detailed a small retrospective study of adults in a commercial weight-management program. These participants used semaglutide or tirzepatide alongside supervised exercise and dietitian support. The study was led by Meral Kucuk Yetgin of the School of Public Health-Bloomington at Indiana University and published online in Obesity Pillars.
The 11-person study is part of a wider research discussion about how body composition changes during medication-assisted weight loss, and whether structured exercise and nutrition support can influence those changes. When adults use incretin-based medications, changes in body weight involve both fat mass and lean mass. To track these distinct tissues accurately, researchers in this study measured fat and lean mass using DEXA scans before and after the program.
Understanding the function of different tissues helps clarify why these measurements matter. Lean mass includes skeletal muscle, bone, and water. A separate 2026 review cautions that lean-mass loss is not equivalent to sarcopenia by itself. Sarcopenia involves a broader medical diagnosis, not just a numerical reduction in lean tissue mass.
Therefore, body-composition estimates alone should not be treated as proof of clinically meaningful muscle impairment. Avoiding the assumption that a change in lean mass guarantees a diagnosis of sarcopenia is essential for a clear understanding of metabolic health. Distinguishing scale weight from body composition is a critical step when discussing weight change with a clinician or dietitian.
The program studied by the researchers combined medical treatment with specific, measurable behavioral habits. It set weekly aerobic-activity targets of 150 to 300 minutes of moderate activity or 75 to 150 minutes of vigorous activity. Participants also completed at least two supervised strength-training sessions per week. Additionally, the program provided individualized diet advice to support their changing energy needs.
It is easy to look at preliminary study results and conclude that a specific exercise and diet routine perfectly preserves muscle during weight loss. In the study analysis, researchers attributed 87.6% of the average weight lost to fat mass and only 12.4% to lean mass. However, this 87.6% result describes a small, selected program cohort. Because the analysis was retrospective and uncontrolled, it cannot show whether the program's exercise and nutrition support actually caused the observed results.
The sample selection introduces important nuances that narrow the scope of these findings. Only 11 of 25 people screened were included in the final analysis. The report says those included differed from excluded individuals in baseline characteristics such as body weight and body composition.
Furthermore, the report notes no external funding and states that several authors were affiliated with Apeiron Life, where the study was conducted. These factors remind us to treat the 87.6% figure as an encouraging observation rather than a demonstrated typical outcome for all adults using semaglutide or tirzepatide.
Broader estimates across the scientific literature present a more varied picture of body composition changes. A 2026 review article reports that in a DXA substudy of tirzepatide, approximately 74% of weight loss was fat mass and 26% lean mass. Another 2026 review summarizes a meta-analysis in which fat mass accounted for more weight loss than lean mass across the treatments discussed. The small program study reports a much lower 12.4% lean mass share, highlighting the need to view isolated program data alongside larger clinical assessments.
For professionals trying to evaluate the shift toward multi target obesity drugs, understanding this variation is critical.
The researchers tracked this specific group of adults to gather precise clinical observations over the course of the intervention. They analyzed 11 adults, with a mean age of 53.46 years. The cohort was 81.8% men, and their median starting BMI was 28.7. Three participants received semaglutide, while eight received tirzepatide during the observation window.
The sample was too small to compare outcomes between semaglutide and tirzepatide directly. Over a median follow-up of 277 days, participants lost an average of 4.99 kg, which represented 4.71% of their starting body weight. Fat mass fell by 4.37 kg, or 11.06%, a change that was statistically significant. The average lean mass fell by 0.62 kg, or 0.94%, but that specific change was not statistically significant.
A nonsignificant lean-mass change does not establish that no lean mass was lost. It simply means the observed average decrease of 0.62 kg did not reach the threshold for statistical significance in this small group. For people looking into reframing physical activity in obesity care, this data reinforces that structured movement continues to be a central topic of study for body composition.
The study authors stated that these findings support further investigation of structured exercise and nutritional support as possible strategies for minimizing lean-mass loss during weight reduction with incretin-based drugs. Future clinical trials will require much larger sample sizes and rigorous control groups to prove that specific habits directly preserve muscle tissue. For individuals navigating these treatments, the assembled evidence supports asking a healthcare provider about incorporating nutrition and resistance exercise into a broader plan. As the medical community reassesses obesity care in a new era of treatment, observing how structured lifestyle adjustments interact with advanced medications will remain a critical focus.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
